Cartilage LesionNCT06932380
A Talus Implant in Patients Between 20-60 Years of Age Followed up for a Minimum of 2 Years After Surgery
A study testing Talus prosthesis in people with Cartilage Lesion, run by Vestre Viken Hospital Trust at 1 site in Norway.
Trial summary
The project will investigate safety, feasibility and efficiency when using Episurf Episeal talus implant in patients with osteochondral ankle injuries. Assessments includes revision rate, complications, pain, function and quality of life over two years. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Cartilage Lesion
- What is being tested?
- Talus prosthesis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteNorway
- Study dates
- 1 Oct 2024to 31 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients aged 20-60 years with symptomatic osteochondral lesions of the ankle where conservative treatment or previous surgery has been unsatisfactory.
- Patients with a limited cartilage defect that qualifies for Episealer implantation.
- Patients who have provided written informed consent to participate in the study.
Who cannot join
- Patients with an active infection in the ankle.
- Patients with extensive cartilage damage where Episealer is not indicated.
- Patients with osteoarthritic changes on the tibial side of the ankle joint.
- Patients with severe joint instability.
- Patients with severe neurological or systemic diseases.
- Patients who smoke.
- Patients with substance abuse issues.
- Patients unable to attend follow-ups due to distance or other factors.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Norway1 site, 1 recruiting
- Recruiting
Drammen Sykehus
Drammen, 3004
Per Reidar Høiness, MD Phd, +47 975 27 911, prhoines@vestreviken.no
Trond Erlend Dalen, MD, 047 32 80 38 46, trdale@vestreviken.no
About this study
Official title: A Talus Implant in Patients Between 20-60 Years of Age Followed up for a Minimum of 2 Years After Surgery: A Pilot Study
The project will investigate safety, feasibility and efficiency when using Episurf Episeal talus implant in patients with osteochondral ankle injuries. Assessments includes revision rate, complications, pain, function and quality of life over two years. Ten patients (aged 20-60) who have not responded to previous treatment will participate based on informed and written consent. The project uses a prospective cohort design where the patients receive a customized surgical procedure. Data on clinical function, pain and patient satisfaction collected using the AOFAS ankle score, NRS and EQ-5D-5L questionnaire at 6 weeks, 6 months, 1 year and 2 years after the operation. The study can provide valuable insight into the treatment of ankle osteoarthritis, improve the patient's quality of life and function, and represent a step forward in orthopedic surgery, especially for younger, active patients. The results are shared with it the medical community and the general public through publications and presentations.
Read the detailed description
Localized cartilage injuries in the ankle occur when distinct areas of the cartilage in the ankle joint become damaged or worn down. This can lead to pain, swelling, reduced mobility and function, and an increased risk of osteoarthritis over time. The challenge with these injuries is that cartilage has a limited capacity for self-healing due to its lack of direct blood supply. Treatment options remain limited, as conventional methods such as physiotherapy or anti-inflammatory medications only address symptoms rather than the underlying damage. More invasive procedures, such as joint replacement or extensive reconstructive surgery, are associated with prolonged rehabilitation periods and variable success rates, particularly in younger, active patients. This highlights the need for precise, customized treatment solutions that can directly repair the damage and effectively restore joint function. A patient-specific implant has been designed to address focal cartilage injuries in joints, primarily in the knee but also in the ankle. The implant is based on advanced imaging and 3D modeling to adapt to the patient's unique joint anatomy and extent of injury. The method involves open surgery to replace the damaged cartilage and adjacent bone with a metal implant (cobalt-chromium) that mimics the patient's original joint surface. This facilitates targeted pain relief and improved joint function, offering a personalized treatment alternative for patients with localized cartilage defects. Compared to traditional ankle joint replacements or arthrodesis, the use of this implant is considered less invasive and associated with a shorter recovery period, reducing patient burden and allowing for a quicker return to daily activities. Additionally, the patient-specific design of the implant has the potential to minimize implant-related complications, such as implant wear and implant-related pain. Early clinical studies on this implant have shown promising results regarding pain relief, improved joint function, and patient satisfaction. However, only a limited number of reports exist to date, and further studies are needed to assess the long-term effects of the implant on pain, function, and quality of life.
The implant may represent a significant advancement in orthopedic surgery and has the potential to improve the quality of life for patients suffering from ankle joint injuries and osteochondral lesions.
In conjunction with the introduction of this method and implant, particularly in younger patients, the investigators aim to conduct a pilot study on the early outcomes of the first ten patients, focusing on safety, feasibility, and efficacy.
This project aims to evaluate the surgical outcomes in patients aged 20 to 60 years with challenging cartilage injuries in the ankle, two years postoperatively following implantation of a custom-made talus implant. The study focuses on safety, feasibility, and efficacy. Complications and adverse events will be recorded.
Clinical function will be assessed using the American Orthopaedic Foot and Ankle Society (AOFAS) hindfoot score, a well-validated and reliable scoring system, while HRQoL will be assessed using the EQ-5D-5L score.
Ten patients with osteochondral lesions will be included in the study. Patients will be selected from a clinical population with moderate to severe symptoms and will be treated at an orthopedic clinic (DS) with expertise in managing ankle osteoarthritis/cartilage injuries and performing the talus implant implantation. Through this recruitment process, the investigators aim to establish a cohort that reasonably reflects the patient population with ankle osteoarthritis at our clinic, thereby enhancing the quality and relevance of the research.
Upon inclusion, patients will undergo a clinical examination, X-ray, and MRI imaging of the foot to assess the extent of the injury and joint geometry. The Berndt-Harty classification system will be used to categorize the injury based on radiographic images, and the Bristol-Hepple classification will be employed to describe lesion size, edema, displacement, and cyst formation based on MRI images. Patients will undergo implantation of the talus implant performed by a qualified orthopedic surgical team. Pre- and postoperative pain management protocols will be implemented. Standard postoperative follow-up plans, including rehabilitation and physiotherapy, will be provided. Patients will be followed up clinically at 6 weeks, 6 months, 1 year, and 2 years postoperatively.
Additional data collected include: Demographic data: Age, sex, surgical time (minutes).
Clinical data: Time of diagnosis, treatment initiation, treatment type, and treatment course.
Patients will be informed about the study and will provide written consent before inclusion. To ensure ethical and legal informed consent, patients will receive a detailed consent form explaining the nature of the study, what participation entails, and how patient data will be managed to protect confidentiality. Only after obtaining written consent will patients be included in the study.
In this study, the power calculation is challenged by a limited patient sample, which affects the potential for statistical significance. With a single cohort of 10 patients over a two-year period, the sample size restricts the ability to detect statistically significant differences in AOFAS and EQ-5D-5L scores. Reduced statistical power is an inherent consequence of the small sample size. The results, primarily descriptive and exploratory, must be interpreted with caution and regarded as a foundation for further research. Alternative analytical approaches will be considered to maximize the value of the collected data.
The following data processing and statistical analysis methods are planned:
- Descriptive statistics to summarize demographic and baseline clinical characteristics of participants.
- T-tests or Wilcoxon signed-rank tests to compare pre- and postoperative outcomes on continuous variables such as pain (NRS), AOFAS scores, and HRQoL (EQ-5D-5L), depending on data distribution.
- ANOVA or Kruskal-Wallis tests for comparisons across multiple time points or groups.
- Linear regression models to analyze relationships between predictors (e.g., age, sex, injury severity) and outcome variables (e.g., pain, function, HRQoL).
- Calculation of the Minimum Clinically Important Difference (MCID) for EQ-5D-5L to establish the smallest score change perceived as clinically meaningful by patients.
- Kaplan-Meier survival analysis to estimate revision rates over time.
- Cox proportional hazards models to assess risk factors for potential implant revisions. A detailed analysis plan will be developed before data collection begins to ensure that the study has sufficient power to detect any significant differences or associations.
- Conditions
- Cartilage Lesion
- Being tested
- Talus prosthesis
- Keywords
- focal cartilage injury, ankle cartilage, patient-specific implant, pilot study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Talus prosthesisProcedure or surgery
The Episealer Talus is an individualised resurfacing implant intended for use on either the medial or lateral talus. It aims to treat patients suffering from pain and reduced mobility due to focal osteochondral lesions in the talus.
| Study group | Role | What they receive |
|---|---|---|
| Talus prosthesis | Experimental | This study consists of a single-arm intervention evaluating the Episurf Episealer talus implant in patients with symptomatic osteochondral lesions of the ankle. All included patients will undergo open surgical implantation of the patient-specific cobalt-chromium implant, designed to restore joint congruency and improve function. Standardized postoperative care, including rehabilitation and follow-up assessments at 6 weeks, 6 months, 1 year, and 2 years, will be provided. Primary outcomes include revision rate and complication incidence, while secondary measures assess pain, functional improvement, and health-related quality of life. Receives: Procedure: Talus prosthesis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients undergoing revision surgery
Revision surgery involves replacing or removing part or all of the talus prosthesis. This may be necessary in the event of various problems with the prosthesis, for example that the prosthesis has loosened from the bone, wear of the prosthesis materials, infection or if the prosthesis dislocates.
Measured: From the time of the index surgery throughout the entire 24-month follow-up period.
Secondary outcomes (4)
Patient satisfaction on a scale from 0 to 10
Patient satisfaction is assessed by the use of NRS, or Numerical Rating Scale, which is a widely used method for assessing patients' experience of satisfaction. It consists of a scale from 0 to 10, where 0 represents or "completely dissatisfied" and 10 indicates "completely satisfied".
Patients are asked to rate their satisfaction level by selecting a number that best describes their current condition.
The NRS is easy to administer and understand, and can be used in a number of medical and research contexts to quantify degree of satisfaction.
This method is particularly useful for following changes in the patient's condition over time, as well as evaluating the effect of treatments or interventions. In assessments of satisfaction, the person answers a standard question from the project staff. The NRS has been found to be both reliable and valid and is widely used when assessing satisfaction.
Measured: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
Patient pain on a scale from 0 to 10
Pain is assessed by the use of NRS, or Numerical Rating Scale, which is a widely used method for assessing patients' experience of pain. It consists of a scale from 0 to 10, where 0 represents "no pain" and 10 indicates "worst imaginable pain".
Patients are asked to rate their pain level by selecting a number that best describes their current condition.
The NRS is easy to administer and understand, and can be used in a number of medical and research contexts to quantify pain intensity. This method is particularly useful for following changes in the patient's condition over time, as well as evaluating the effect of treatments or interventions. In assessments of pain, the person answers a standard question from the project staff. The NRS has been found to be both reliable and valid and is widely used when assessing pain.
Measured: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
AOFAS ankle score on a scale from 0 to 100
The American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Rating System is a standardized evaluation of the clinical status of the ankle-hindfoot. It incorporates both subjective and objective information. Patients report their pain, and physicians assess alignment. The patient and physician work together to complete the functional portion. Scores range from 0 to 100, with healthy ankles receiving 100 points.
This score may be used to assess the ankle, subtalar, talonavicular, and calcaneocuboid joint levels and may be useful for fractures, arthroplasty, arthrodesis, and instability procedures.
Measured: Baseline - from the time of the index surgery throughout the entire 24-month follow-up period.
EQ-5D-5L score
The EQ-5D-5L (European Quality of Life 5 Dimensions 5 Level Version) is a generic tool for Patient-Reported Outcomes (PRO) measurement that can assess patients' quality of life, irrespective of the disease.
The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
Measured: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start1 Oct 2024
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cartilage LesionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This interventional pilot study employs a prospective cohort design to evaluate the safety, feasibility, and efficacy of the patient-specific Episurf Episealer talus implant in treating osteochondral lesions of the ankle. Ten patients aged 20 to 60 years with symptomatic cartilage defects unresponsive to conservative or prior surgical treatment will be included. The intervention consists of open surgical implantation of a custom-made cobalt-chromium implant tailored to each patient's joint anatomy. Outcomes will be assessed through clinical function scores (AOFAS), pain and satisfaction measures (NRS), and health-related quality of life (EQ-5D-5L) over a two-year follow-up period. The study aims to provide preliminary evidence on the implant's clinical performance, with revision rates and complications as primary endpoints.
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vestre Viken Hospital Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06932380
- Sponsor's protocol ID
- 24/09300-3
- Status last verified
- Apr 2025
- First submitted
- 31 Mar 2025
- Last updated
- 29 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Sharing IPD is not prohibited by the Ethics Committee and will thus not be done.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Talus Implant in Patients Between 20-60 Years of Age Followed up for a Minimum of 2 Years After Surgery: A Pilot Study
- ClinicalTrials.gov ID
- NCT06932380
- Acronym / sponsor ID
- 24/09300-3
- Conditions
- Cartilage Lesion
- Keywords
- focal cartilage injury, ankle cartilage, patient-specific implant, pilot study
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Vestre Viken Hospital TrustUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The project will investigate safety, feasibility and efficiency when using Episurf Episeal talus implant in patients with osteochondral ankle injuries. Assessments includes revision rate, complications, pain, function and quality of life over two years. Ten patients (aged 20-60) who have not responded to previous treatment will participate based on informed and written consent. The project uses a prospective cohort design where the patients receive a customized surgical procedure. Data on clinical function, pain and patient satisfaction collected using the AOFAS ankle score, NRS and EQ-5D-5L questionnaire at 6 weeks, 6 months, 1 year and 2 years after the operation. The study can provide valuable insight into the treatment of ankle osteoarthritis, improve the patient's quality of life and function, and represent a step forward in orthopedic surgery, especially for younger, active patients. The results are shared with it the medical community and the general public through publications and presentations.
Detailed description
Localized cartilage injuries in the ankle occur when distinct areas of the cartilage in the ankle joint become damaged or worn down. This can lead to pain, swelling, reduced mobility and function, and an increased risk of osteoarthritis over time. The challenge with these injuries is that cartilage has a limited capacity for self-healing due to its lack of direct blood supply. Treatment options remain limited, as conventional methods such as physiotherapy or anti-inflammatory medications only address symptoms rather than the underlying damage. More invasive procedures, such as joint replacement or extensive reconstructive surgery, are associated with prolonged rehabilitation periods and variable success rates, particularly in younger, active patients. This highlights the need for precise, customized treatment solutions that can directly repair the damage and effectively restore joint function. A patient-specific implant has been designed to address focal cartilage injuries in joints, primarily in the knee but also in the ankle. The implant is based on advanced imaging and 3D modeling to adapt to the patient's unique joint anatomy and extent of injury. The method involves open surgery to replace the damaged cartilage and adjacent bone with a metal implant (cobalt-chromium) that mimics the patient's original joint surface. This facilitates targeted pain relief and improved joint function, offering a personalized treatment alternative for patients with localized cartilage defects. Compared to traditional ankle joint replacements or arthrodesis, the use of this implant is considered less invasive and associated with a shorter recovery period, reducing patient burden and allowing for a quicker return to daily activities. Additionally, the patient-specific design of the implant has the potential to minimize implant-related complications, such as implant wear and implant-related pain. Early clinical studies on this implant have shown promising results regarding pain relief, improved joint function, and patient satisfaction. However, only a limited number of reports exist to date, and further studies are needed to assess the long-term effects of the implant on pain, function, and quality of life.
The implant may represent a significant advancement in orthopedic surgery and has the potential to improve the quality of life for patients suffering from ankle joint injuries and osteochondral lesions.
In conjunction with the introduction of this method and implant, particularly in younger patients, the investigators aim to conduct a pilot study on the early outcomes of the first ten patients, focusing on safety, feasibility, and efficacy.
This project aims to evaluate the surgical outcomes in patients aged 20 to 60 years with challenging cartilage injuries in the ankle, two years postoperatively following implantation of a custom-made talus implant. The study focuses on safety, feasibility, and efficacy. Complications and adverse events will be recorded.
Clinical function will be assessed using the American Orthopaedic Foot and Ankle Society (AOFAS) hindfoot score, a well-validated and reliable scoring system, while HRQoL will be assessed using the EQ-5D-5L score.
Ten patients with osteochondral lesions will be included in the study. Patients will be selected from a clinical population with moderate to severe symptoms and will be treated at an orthopedic clinic (DS) with expertise in managing ankle osteoarthritis/cartilage injuries and performing the talus implant implantation. Through this recruitment process, the investigators aim to establish a cohort that reasonably reflects the patient population with ankle osteoarthritis at our clinic, thereby enhancing the quality and relevance of the research.
Upon inclusion, patients will undergo a clinical examination, X-ray, and MRI imaging of the foot to assess the extent of the injury and joint geometry. The Berndt-Harty classification system will be used to categorize the injury based on radiographic images, and the Bristol-Hepple classification will be employed to describe lesion size, edema, displacement, and cyst formation based on MRI images. Patients will undergo implantation of the talus implant performed by a qualified orthopedic surgical team. Pre- and postoperative pain management protocols will be implemented. Standard postoperative follow-up plans, including rehabilitation and physiotherapy, will be provided. Patients will be followed up clinically at 6 weeks, 6 months, 1 year, and 2 years postoperatively.
Additional data collected include: Demographic data: Age, sex, surgical time (minutes).
Clinical data: Time of diagnosis, treatment initiation, treatment type, and treatment course.
Patients will be informed about the study and will provide written consent before inclusion. To ensure ethical and legal informed consent, patients will receive a detailed consent form explaining the nature of the study, what participation entails, and how patient data will be managed to protect confidentiality. Only after obtaining written consent will patients be included in the study.
In this study, the power calculation is challenged by a limited patient sample, which affects the potential for statistical significance. With a single cohort of 10 patients over a two-year period, the sample size restricts the ability to detect statistically significant differences in AOFAS and EQ-5D-5L scores. Reduced statistical power is an inherent consequence of the small sample size. The results, primarily descriptive and exploratory, must be interpreted with caution and regarded as a foundation for further research. Alternative analytical approaches will be considered to maximize the value of the collected data.
The following data processing and statistical analysis methods are planned:
- Descriptive statistics to summarize demographic and baseline clinical characteristics of participants.
- T-tests or Wilcoxon signed-rank tests to compare pre- and postoperative outcomes on continuous variables such as pain (NRS), AOFAS scores, and HRQoL (EQ-5D-5L), depending on data distribution.
- ANOVA or Kruskal-Wallis tests for comparisons across multiple time points or groups.
- Linear regression models to analyze relationships between predictors (e.g., age, sex, injury severity) and outcome variables (e.g., pain, function, HRQoL).
- Calculation of the Minimum Clinically Important Difference (MCID) for EQ-5D-5L to establish the smallest score change perceived as clinically meaningful by patients.
- Kaplan-Meier survival analysis to estimate revision rates over time.
- Cox proportional hazards models to assess risk factors for potential implant revisions. A detailed analysis plan will be developed before data collection begins to ensure that the study has sufficient power to detect any significant differences or associations.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This interventional pilot study employs a prospective cohort design to evaluate the safety, feasibility, and efficacy of the patient-specific Episurf Episealer talus implant in treating osteochondral lesions of the ankle. Ten patients aged 20 to 60 years with symptomatic cartilage defects unresponsive to conservative or prior surgical treatment will be included. The intervention consists of open surgical implantation of a custom-made cobalt-chromium implant tailored to each patient's joint anatomy. Outcomes will be assessed through clinical function scores (AOFAS), pain and satisfaction measures (NRS), and health-related quality of life (EQ-5D-5L) over a two-year follow-up period. The study aims to provide preliminary evidence on the implant's clinical performance, with revision rates and complications as primary endpoints.
| Arm | Type | Receives |
|---|---|---|
| Talus prosthesis | Experimental | Procedure: Talus prosthesisThis study consists of a single-arm intervention evaluating the Episurf Episealer talus implant in patients with symptomatic osteochondral lesions of the ankle. All included patients will undergo open surgical implantation of the patient-specific cobalt-chromium implant, designed to restore joint congruency and improve function. Standardized postoperative care, including rehabilitation and follow-up assessments at 6 weeks, 6 months, 1 year, and 2 years, will be provided. Primary outcomes include revision rate and complication incidence, while secondary measures assess pain, functional improvement, and health-related quality of life. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Patients aged 20-60 years with symptomatic osteochondral lesions of the ankle where conservative treatment or previous surgery has been unsatisfactory.
- Patients with a limited cartilage defect that qualifies for Episealer implantation.
- Patients who have provided written informed consent to participate in the study.
Key exclusion criteria (8 listed)
- Patients with an active infection in the ankle.
- Patients with extensive cartilage damage where Episealer is not indicated.
- Patients with osteoarthritic changes on the tibial side of the ankle joint.
- Patients with severe joint instability.
- Patients with severe neurological or systemic diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Talus prosthesisThe Episealer Talus is an individualised resurfacing implant intended for use on either the medial or lateral talus. It aims to treat patients suffering from pain and reduced mobility due to focal osteochondral lesions in the talus. | Procedure or surgery | Talus prosthesis |
Primary outcome
Number of patients undergoing revision surgery
Time frame: From the time of the index surgery throughout the entire 24-month follow-up period.
Revision surgery involves replacing or removing part or all of the talus prosthesis. This may be necessary in the event of various problems with the prosthesis, for example that the prosthesis has loosened from the bone, wear of the prosthesis materials, infection or if the prosthesis dislocates.
4 secondary outcomes
Patient satisfaction on a scale from 0 to 10
Time frame: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
Patient pain on a scale from 0 to 10
Time frame: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
AOFAS ankle score on a scale from 0 to 100
Time frame: Baseline - from the time of the index surgery throughout the entire 24-month follow-up period.
EQ-5D-5L score
Time frame: Baseline - from the time of the index surgery - throughout the entire 24-month follow-up period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2025.
- Individual participant dataSharing planned: No. Sharing IPD is not prohibited by the Ethics Committee and will thus not be done.
Related trials for Cartilage Lesion
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
RecruitingPhase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Knee Cartilage Defects
RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Chondral Defect, Articular Cartilage Defect
Not yet recruitingObservational study
Laryngotracheal Lesions in Adults With Long-Term Tracheostomy
Laryngotracheal Lesions, Tracheostomy Complications
Active, not recruiting
Episealer® Knee System IDE Clinical Study
Degenerative Lesion of Articular Cartilage of Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Talus prosthesis in people with Cartilage Lesion, run by Vestre Viken Hospital Trust at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients undergoing revision surgery (time frame: From the time of the index surgery throughout the entire 24-month follow-up period.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2025.